China's National Medical Products Administration has approved GSK's belantamab mafodotin in combination with bortezomib and dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a B-cell maturation antigen-directed antibody-drug conjugate composed of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F through a non-cleavable linker.
The approval is notable because the product's development path has been unusually turbulent. Belantamab mafodotin first won approvals in the United States and Europe in 2020 based on the phase 2 DREAMM-2 study, but it was later withdrawn from Western markets after the confirmatory DREAMM-3 trial failed. GSK then pivoted to combination development and ultimately delivered a turnaround with the phase 3 DREAMM-7 study. In that trial, belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival versus daratumumab plus bortezomib and dexamethasone, extending median PFS to 36.6 months versus 13.4 months and reducing the risk of disease progression or death by about 60%. Overall survival also improved, with a 42% reduction in the risk of death at a median follow-up of 39.4 months.
The Chinese approval gives clinicians another BCMA-targeted option in a market where multiple myeloma treatment is increasingly diversified across ADCs, bispecific antibodies, and CAR-T therapies. According to the source article, only a small number of BCMA ADCs remain in active global clinical development, while the target has become far more crowded in CAR-T and bispecific formats. Against that backdrop, belantamab mafodotin's re-entry through combination therapy could broaden treatment choice, especially if its efficacy profile continues to hold up in practice and ocular adverse events remain manageable with dose adjustment and follow-up.